U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Thymic Carcinoma

MedGen UID:
1665520
•Concept ID:
C4724873
•
Neoplastic Process

Definition

Thymic carcinoma that does not respond to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Thymic Carcinoma

Professional guidelines

PubMed

Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma.
Okuma Y, Hosomi Y, Miyamoto S, Shibuya M, Okamura T, Hishima T
BMC Cancer 2016 Feb 25;16:156. doi: 10.1186/s12885-016-2159-7. PMID: 26915359Free PMC Article
Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations.
Okuma Y, Hosomi Y, Watanabe K, Takahashi S, Okamura T, Hishima T
Int J Clin Oncol 2016 Jun;21(3):531-8. Epub 2015 Dec 8 doi: 10.1007/s10147-015-0926-0. PMID: 26646221

Recent clinical studies

Etiology

Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network.
Remon J, Girard N, Mazieres J, Dansin E, Pichon E, Greillier L, Dubos C, Lindsay CR, Besse B
Lung Cancer 2016 Jul;97:99-104. Epub 2016 May 3 doi: 10.1016/j.lungcan.2016.04.024. PMID: 27237035
Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma.
Okuma Y, Hosomi Y, Miyamoto S, Shibuya M, Okamura T, Hishima T
BMC Cancer 2016 Feb 25;16:156. doi: 10.1186/s12885-016-2159-7. PMID: 26915359Free PMC Article
Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations.
Okuma Y, Hosomi Y, Watanabe K, Takahashi S, Okamura T, Hishima T
Int J Clin Oncol 2016 Jun;21(3):531-8. Epub 2015 Dec 8 doi: 10.1007/s10147-015-0926-0. PMID: 26646221
Docetaxel for platinum-refractory advanced thymic carcinoma.
Watanabe N, Umemura S, Niho S, Kirita K, Matsumoto S, Yoh K, Ohmatsu H, Goto K
Jpn J Clin Oncol 2015 Jul;45(7):665-9. Epub 2015 Apr 2 doi: 10.1093/jjco/hyv046. PMID: 25840444

Diagnosis

Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network.
Remon J, Girard N, Mazieres J, Dansin E, Pichon E, Greillier L, Dubos C, Lindsay CR, Besse B
Lung Cancer 2016 Jul;97:99-104. Epub 2016 May 3 doi: 10.1016/j.lungcan.2016.04.024. PMID: 27237035
Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma.
Okuma Y, Hosomi Y, Miyamoto S, Shibuya M, Okamura T, Hishima T
BMC Cancer 2016 Feb 25;16:156. doi: 10.1186/s12885-016-2159-7. PMID: 26915359Free PMC Article

Therapy

Sustained antitumor response to lenvatinib with weekend-off and alternate-day administration in chemotherapy-refractory thymic carcinoma: a case report.
Sunaga N, Miura Y, Sakurai R, Ohshima S, Uno S, Muto S, Sato M, Tsurumaki H, Yatomi M, Koga Y, Ohtaki Y, Nagashima T, Okano N, Kubo N, Maeno T, Hisada T
Anticancer Drugs 2023 Apr 1;34(4):605-608. Epub 2022 Dec 5 doi: 10.1097/CAD.0000000000001474. PMID: 36729850
Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network.
Remon J, Girard N, Mazieres J, Dansin E, Pichon E, Greillier L, Dubos C, Lindsay CR, Besse B
Lung Cancer 2016 Jul;97:99-104. Epub 2016 May 3 doi: 10.1016/j.lungcan.2016.04.024. PMID: 27237035
Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma.
Okuma Y, Hosomi Y, Miyamoto S, Shibuya M, Okamura T, Hishima T
BMC Cancer 2016 Feb 25;16:156. doi: 10.1186/s12885-016-2159-7. PMID: 26915359Free PMC Article
Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations.
Okuma Y, Hosomi Y, Watanabe K, Takahashi S, Okamura T, Hishima T
Int J Clin Oncol 2016 Jun;21(3):531-8. Epub 2015 Dec 8 doi: 10.1007/s10147-015-0926-0. PMID: 26646221
Docetaxel for platinum-refractory advanced thymic carcinoma.
Watanabe N, Umemura S, Niho S, Kirita K, Matsumoto S, Yoh K, Ohmatsu H, Goto K
Jpn J Clin Oncol 2015 Jul;45(7):665-9. Epub 2015 Apr 2 doi: 10.1093/jjco/hyv046. PMID: 25840444

Prognosis

Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma.
Okuma Y, Hosomi Y, Miyamoto S, Shibuya M, Okamura T, Hishima T
BMC Cancer 2016 Feb 25;16:156. doi: 10.1186/s12885-016-2159-7. PMID: 26915359Free PMC Article

Clinical prediction guides

Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma.
Okuma Y, Hosomi Y, Miyamoto S, Shibuya M, Okamura T, Hishima T
BMC Cancer 2016 Feb 25;16:156. doi: 10.1186/s12885-016-2159-7. PMID: 26915359Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...